ヽ

′HealthCaFe
VentureConference
KYOT0 201911→

ごly lst,20191』

Kyoto Research lParlk West i31dg#4 BlF

Venue

250 paftiCipants tirsr-c0me{irsr-served basis)

Free

X Prior application required
HVC KY0T0 2019 Secretariat

Kyoto Research Park Corp.

Registration URL

E-mail: hvckyoto@krp.co.ip
TEL: 075-31 5-9040

珊

主催 :日 本貿易振興機構 (3ETRO)、 京都府、京都市、京都 リサーチバーク株式会社
共催 :京 都大学産官学連携本部′

後援 =近 畿経済産業局 、京都商二会議所、大 阪商工会議所 、神戸商工会議所 、公益財団法人都市活力研究所、NPO法 人 晴 西健康・医療学術連絡会」、
イノベー シヨン・ネツトワーク・ジヤバン(LttK― J)、 NPO法 人日本 MITベ ンチャーフォーラム、合同会社 SARR
医療創生会議、一般社団法人ライフサイエンス‐
関西健康 ‐

ヽ

・

曇 一
一■■●
一 ・
■■．
一 一■■■
■■一．

︲
■一■ ・
．
一■ ●

■●■●

一 一一
一

一 ．

一
一
■一
■一
・

●
■
一■●
・
・
■
一■ 二
●■
■
■ ■■

20+SCientiStS and Venture CapitalS WhO VA〆 iSh t0 0Xpand inSide and OutSide Of Japan

ⅥЛIl be haVing tineir English pitchln front of a podium.For those searching for lnnovative technology in healthcare,please feelfree to ioin the conference※HVCKYOT02019 will be held as a part of JETRO's「 Reglonal Promotion Prolect」 and「 Reglona1 8uslness Conference」
There ぃ′￨￨l be a Japanese‐ Engllsh interpreter lWIIl be lendlng out receivers to those ln need)'￨lrTlited arinounts

Program
9:30

0pening remarks

9:40@l@ Design-driven approaches to drug discovery and translational research
Rieko Yalima, Ph.D.

ヽ燿

Director, Druq Disc0very nn0vation

ヽコ

Stanford Llniversity

SPARK Prograrn in Translatronal Research

Schoo of lvledicine

10115 1 Pitch sesslon11・

12115

:

Lunch break

13:15

1

Boston sesslon

istanups&ventures frOm BOstOn area whO wish 10 deve10p

ltheir buSineSS in Japan'´ ′￨￨l be haVing tnetr DltC11 1n thlS SeSS10n

15:00 : Pitch sessioo11::,20+

17:00 : Networklng(At tte exhibition ha‖ )innovativeヾEach sesslon speaker please refer to V'′ EB

Pitch

14:45 i￨ヽ

Coffee break

HVC KYOT0 2019 Partners
Platinum
″′

´

｀

ヽ

rPank イ九&,が ヽ J』
Shonan

´ヽ
―
■E

H爾

爾

Gold

腱

′鵬

m十

肺

m iNNOVAriO譴卜

Silver―BA]ERノ

●

鶴

.
ヽ
イエリじ

Nご yER S■ γ NEソ[R

肋 義許予 藝

、多多二

Hoche

rhraruhoEYi\e+t*ii,'t3ifi$"",rfi{f;を、想う呻 KYOTO― iCAP

4

小林 製薬

面aryv二 月AdP

沙 raRP口 児四コralⅣ2019 Pitch Presenters
Session 1

Affiliation

Name of Speaker

Title

SkySea Pharmaceutical Inc.

Yuji Kogami

Drug Discovery of Oxytocin related Autism Spectrum Disorder1

12006 AsahiKasei Pharmaceutical
2006-2010 PRISM BioLab Corporation Director
2010- D.D.P. Corporation, CEO & President
2015- SkySea Pharmaceutical Inc., CEO & President

2

ReguGene Co., Ltd.

Shuji Ikeda

Epigenetic Drug Discovery by Gene Switch

Ph.D. Managing Director of ReguGene Co., Ltd. and researcher at Chemistry Department, Graduate School of Kyoto University afterworking as assistant professor and researcher at university, national research institute, and venture company in Singapore.

3

Cellagility Biomed Pvt. Co.

Kouichi Hasegawa

Enabling Cell Therapy – From India to world –Junior Associate Prof. Institute for Integrated Cell-Material Sciences (iCeMS),Kyoto University, and Scientific Advisory board, Cellagility
Biomed, India.Previously served as a faculty in University of Southern California, Universityof Melbourne and inStem, India, and a SAB at
Cell Guidance System (UK) and Stem Cell Innovation (Japan).
4

iBody Inc.

Teruyo Kato

Robust screening of monoclonal antibodies from rabbits
and humans

Graduate school of Nagoya University/R&D section at food material company/Reseacher of Project at Knowledge Hub Aichi/JSPS PD
Reseach fellowship/CEO at iBody

5

ERISA Co., LTD.

Yoshiyuki NOTSU

Companion Diagnostic “AI Program” that enables successful
development of therapeutic drugs for Alzheimer’s diseases

After completion of master’s degree of Graduate School of Agricultural and Life Sciences, the University of Tokyo, engaged in generalmanagement for overseas subsidiaries and domestic business development for Japanese research reagents manufacture. After 13
years’ employment, joined two life science start-ups as management. Since October 2017, current position.
6

Biotechnology Research Institute for Drug
Discovery, National Institute of Advanced
Industrial Science and Technology

Tadashi Kimura

Disulfide-Rich Peptides, promising scaffolds forpharmaceuticals, agrichemicals and cosmetics.

Dr. Kimura received Ph.D. from Tsukuba University. He has deep experiences on ion-channel and tarantula venom peptides research.
He is a visiting associate professor at united graduate school of drug discovery and medical information science, Gifu University.

7

School of Dentistry, Health Sciences
University of Hokkaido

Takashi Saito

Dentin regeneration therapy using Laminin-derived peptide,
Laminin-411 and 511

The speaker engaged in the research on tooth remineralization and regeneration in UNC Dental Research Center in the United Statesand AIST in Japan, and then since 2003, has been performing the research on the development of novel therapy for deep dental caries
in Health Sciences University of Hokkaido.
8

Tongue Lab

Jean Michel Mauclaire

Paradigm changing curative treatment for sleep apnea.

1991
French Certified Public Accountant, Paris –France
1983-1984 Deloitte & Touche -International audit firm,
1989-1995 Lafarge Group- CFO in a subsidiary,
1996-2000 Lindsey Technologies-Paris,France,Denver,USA:Information Technology startup, CFO
1998-2008 CPA PC– Paris France: Merger and Acquisitions

2002-2011 BioQuanta Corp – Aurora, Co, USA - Paris France:Biotechnology start up: co-founder, CEO.
2012-2016 Management consultant: Growth and technology start-up
companies (France, Mexico)2012
Tongue Lab – London UK - Paris France: founder, Chairman & CEO.
2017
Tongue Lab Japan OfficeElcyo Co., Ltd.

New solution for eye correction “full-range tunable eyeglasses”

9Giichi Shibuya

After graduation from Keio University, Shibuya started working at TDK corp. for 30 years since 1984. At Osaka University He has been
focusing on the research of Fresnel liquid crystal lens since 2014, and launched Elcyo Co., Ltd. in 2019.

Boston Session Special Lecture
Affiliation

Name of Speaker

Title

Biogen Japan Inc

Shinichi Torii

Introduction for new drug development based on Neuroscience research

Born in June, 1960
March, 1984 Graduated from Gifu College of Pharmacy
March, 2002 Ph.D degree from Molecular Biology from Tokyo University,
Graduate School
April, 1984～ Janssen Pharmaceutical K.K.
April, 2007～ Celgene Corporation
April, 2010～ Olympus Corporation
January, 2011～ Olympus Biotech Corporation (Boston, USA)
June, 2014～ Head of R&D, Biogen Japan Inc.
April, 2017～ President & Representative Director, Biogen Japan Inc.
November, 2018～ President & Representative Director, Biogen Japan Inc.
(Daihyo Torishimariyaku Kaicho)

Shinichi joined Biogen Japan in June 2014 to establish and lead its R&D
function in Japan as part of Biogen’s ‘Tri-Hub’ research and development
model. He brings his depth knowledge and experience in both academia andthe industry to leverage the world-class scientific innovation of Biogen. Prior to
Biogen, he spent many years as a researcher in academia and expanded his
career path into the pharmaceutical and medical device industries including
Janssen Pharmaceutical and Olympus Biotech. In his past experiences,
Neurology research and development including MS, Alzheimer’s diseases andgrowth factors, NGF and BDNFs are one of his scientific interests as not only
“bench to bed” but also “bed to bench” collaborations with Japanese basic
and clinical researchers.

Boston Session Pitch Presenters1

2

3

Affiliation

Name of Speaker

Title

biolabs

Christine Kressirer, PhD,

BioLabs, the experience of a biotechnology company in a shared-laboratory facility

1998-2002 Colorado State University BioChemistry,Microbiology
2007-2010 Ludwig-Maximilians University Munich, Doctor ofPhilosophy,(Ph.D),Pharmaceutical Biology andNatural Sciences

2011-2018 The Forsyth Institute
Final title - Director of Core and Laboratory services
2018~
Site Director, Tufts Launchpad Biolabs

UCHU Biosensors, Inc.

Intraoral Health Monitor

Daniel Weinstein

Co-Founder, CEO of UCHU Biosensors, Inc.
2014 - Researcher, Dana Farber Cancer InstituteStudied anti-aptotic cell signaling pathways for drug development2015 - Researcher, Tufts Sackler School of Biomedical Sciences
Grew artificical skin from iPS cells to study chronic wound healing

2016 - Summer Researcher, Technion Institute of Technology
Characterized and validated response of nanoscale opticalbiosensors
2018 - Graduated cum laude with a BSBME (bachelors of science inbiomedical Engineering)from Tufts University School of Engineering

Mytide Therapeutics

High-throughput Peptide Manufacturing for Therapeutic Research and Drug Discovery

Dale A. Thomas III

2013 B.S. Maine Maritime Academy, Valedictorian2013 American Bureau of Shipping Fellowship2014 MEngM, Massachusetts Institute of Technology
2019 PhD, Massachusetts Institute of Technology
2019 Cofounder, Mytide Therapeutics

45

DropGenie

Alison Hirukawa

Automating gene editing using a digital microfludics platform

2011 MSc, Medical Genetics, University of British Columbia, Vancouver,
Canada2017- PhD, Biochemistry, McGill University, Montreal, Canda
2018- Co-founder, Chief Product Officer, DropGenie, Boston MA

North Shore InnoVentures

Innovate faster, Climb higher

Christopher R.C.Ilsley

Chris is the President and CEO of NSIV. As a leader in the Boston innovation
NSIV is an accredited ‘soft landing’ facility for the International Business Incubator
ecosystem Chris and the team at North Shore InnoVentures (NSIV) are actively
Association (InBIA). This accreditation validates that NSIV has a robust and supportive
services and program to help international companies to enter the Boston and North
involved in supporting innovation-driven companies to realize and deliver impact.
Not only does NSIV support companies through start of the art lab facilities; but, also, American life science community. Chris moved to Boston as Head of Science andInnovation at the British Consulate Boston, from Cambridge, UK, where he worked asimportantly, with business and leadership support through programs, services,an advisor to UK companies looking identify and develop international partnershipcommunity partnerships and mentoring.
opportunities.

6

Genomic Expression

Gitte Pedersen

Scientist/CEO with a mission to cure cancer. Started Genomic Expression together withher brother, after her parents were diagnosed with cancer.
The company raised $8M to conduct 4 clinical trials focusing on women cancer first.
OneRNA™ finds the best drug for the patient and the best patient for the drug by
sequencing RNA.
Genomic Expression was in the top 10 of the XTC, also won the Lyfebulb and the
EUTop50 award, and presented at the European Parliament and UN in New York.

7

8

Cellanyx Diagnostics

Guy L. Fish

Title: OneRNA™: a paradigm shift to truly individualized treatment
Prior to Genomic Expression, Gitte advised a number of SMEs of biotech as well as theDanish Ministry of Foreign Affairs with deal resume +$1B.
Gitte Pedersen has a master in Chemical Engineering and a bachelor in International
Trade. She recently joined Pipeline Angels and made her first angel investment.

Stratifying indolent from aggressive cancers: it’s the biology, not the histology

1988-1992 Solo-Practice, Internal Medicine
1995-1999 The Boston Consulting Group, USA
1999-2000 Sanford Bernstein, Equities Analyst, NY, NY
2000-2001 Ivy Consulting Enterprises, Health Care Consulting, Boston, MA
2001-2002 Collagenesis, a tissue engineering firm, Boston, MA
2002-2007 Fletcher Spaght, Inc, Health Care Consulting, Director

2004-2010 Massachusetts Board of Registration in Medicine, MD Licensing
Board,Chairman of Licensing
2010-2016 Dubai Health Care City Licensing Board, Chairman of Board
2005-2018 Fletcher Spaght Venture, Health Care Venture Capital, Vice President
2007-2019 Fletcher Spaght, Inc., Health Care Consulting, Senior Vice President
2019
Cellanyx Diagnostics, CEO

Thrive Bioscience, Inc.

Analytics, AI & Automation in Cell Culture & Stem Cell Culture

Thomas Forest Farb-Horch

Mr. Farb-Horch is CEO and President of Thrive Bioscience (Boston, Massachusetts) which provides (NASD: EXAS), Fair Isaac (NYSE: FIC), Redwood Trust (NYSE: RWT), HNC Software (acquired by Fair
instruments and software tools for the automation of cell culture and stem cell culture, aIsaac), Retek Systems (acquired by Oracle) and Saf-T-Med (acquired by Becton Dickinson).
neglected yet critical area for biomedical research. Thrive has raised $20M to-date, has filed 46
patent applications and is in beta testing of its first of a family of instruments with Harvard Stem
Mr. Farb-Horch has served as President, COO and/or in the senior management of numerous
Cell Institute, Massachusetts General Hospital and Stanford University Stem Cell Core and others. companies, including Thrive Bioscience, Inc., Indevus Pharmaceuticals and Cytyc.
Mr. Farb-Horch has actively participated in the founding of over 10 life sciences, artificial
intelligence and software companies and has had four exits with one billion dollars or more.
He has founded and served on the Boards of numerous companies, including Exact Sciences

9

Biobot Analytics, Inc
2011
2014
2017
2017

10

Canairy
2015
2016-2019
2018
2019

11

Noriko Endo

B.Eng. in Civil Engineering, University of Tokyo, Japan
M.Sci. in Environmental Engineering, Massachusetts institute ofTechnology,USA
PhD in Environmental Engineering, Massachusetts institute ofTechnology, USA
Spatial Epidemiologist and Product Manager, Biobot Analytics, USA

Rayees Rahman

Leveraging wastewater as a window into population health.
Dr. Endo is as engineer who works at the intersection of environmental
engineering and public health. She has extensive field experiences inAfrica, Asia, and North America on health-related projects, such as
malaria transmission, human metabolomics, and antimicrobial resistance.

App based mangement of respiratory disease using cough sounds and machine learning

BS, Biology, Hunter College
PhD Candidate, Computational Biolgy, Icahn School of Medicine at Mount Sinai
Co-founder: A.I.chemy, A.I. based drug discovery platform
CEO and Co-Founder of Canairy; Biotechnology Start up

PORTAL INSTRUMENTS, INC.
2008
2008-20112011-2014
2014-

Mr. Farb has also been a Trustee for numerous non-profit organizations including North Shore
InnoVentures (an incubator/accelerator in the Boston area), Dana Farber Cancer Institute andAsia America Chamber of Commerce. Mr. Farb is a graduate of Harvard University.

Andrew Coats

BS Mechanical Engineering
Cambridge Consultants, Medical Device Engineer
Fractyl Inc., Surgical Device for Diabeaties, Engineer
present Portal Instruments, VP Engineering

Innovation in Drug Delivery: Needle-Free Auto-Injector

2019 Pitch Presenters
Session 2

Affiliation

Name of Speaker

Title

ARTham Therapeutics Inc.

Hiroshi Nagabukuro PhD

Delivering medicines that matter and maximizing pharma asset
value through robust and efficient industry-academia collaborations

1

Dr. Hiroshi Nagabukuro is a co-founder, COO/CSO of newly launched ARTham Therapeutics Inc. He has strong background inpharmacology with >20 years' experience of drug discovery research in both Japan and US. Dr. Nagabukuro also holds special
appointed professorship at Oita University Medical School.
2

Luxonus Inc.

Sadakazu Aiso M.D., PhD.

Photoacoustic 3D imaging opens a Door to Vascular Health
Science

Our new diagnostic equipment using Photoacoustic Imaging technology is non-bombarded, non-invasive, and enables ultra-highresolution 3D imaging of vessels such as blood vessels and lymph vessels. Furthermore, the oxygen saturation of the bloodstream can bevisualized, and it is expected to be utilized for preoperative planning and drug effect verification.
3

aceRNA Technologies

Shin-Il Kim

Solution provider for new pharmaceutical modalities

I obtained Ph.D in 2008 from University of Wisconsin – Madison. After a postdoc at University of California - SF, I received JSPS Postdoctoral
Fellowship to study iPSCs at CiRA, Kyoto University under supervision of Drs. Yamanaka and Woltjen. Currently, I am a director of R&D
division at aceRNA Technologies.
4

HAPPY PROJECT LLC

Masa Kawamukai

Respect aging society and end-of-life medical care at homeby utilizing IoT/AI

He was born and grew up in Kyoto and studied at Liberal Arts College in Oakland, CA both undergraduate and graduate school.
He worked one of big accounting firm and fingerprint venture company in Silicon Valley until dot-com bubble. Since back in Japan, he
worked in several industries including investment firm, hospitality, IT. Now he runs his own small consulting firm and an associate professor/producer at Liberal Arts Innovation Center in Kyoto University Art & Design.
5

Melody International Ltd.

Yhuko Ogata

Save all Mothers and Babies Lives around the Globe～Perinatal e-Health platform

Master of Engineering, Kyoto University Graduate School of Engineering, Nuclear Engineering.
I succeeded in commercialization of the first EMR for Perinatal period at previous company which I founded in 2002. In 2009, I wasawarded "Japan Venture Awards 2009" by the government. Taking advantage of the experiences of medical ICT, I started Melody
International in 2015. The corporate mission as "Providing safe and secure deliveries for all mothers around the World.
6

United Immunity, Co., Ltd.

Naozumi Harada, Ph.D.

Transforming Cold Tumors Hot: A Novel Strategy to Fight Off
Immune Checkpoint Inhibition-Resistant Tumors

20+ years research experience in pharmaceutical companies and biotechs. In a recent decade, has studied cancer immunotherapy
focusing on tumor immune resistance and exploiting nanotechnology to immunotherapy. Recently invented a technology to improve
macrophage function using a Kyoto University-originated unique nanoparticle. To make it as a new weapon against cancer, launched
United Immunity.
7

Metcela Inc.

H. Joon Paek, Ph.D.

Revolutionizing the Way We Treat Heart Failure

After completing university, he established a network of researchers in the US and abroad based on regenerative medicine and medical
devices using adipose-derived stem cells, and has led joint research and business.
Master's : Degree Kyoto University Graduate School of Engineering
doctorate : Brown University, Department of Biology
8

Kyoto University

Yuki Yamamoto, M.D., Ph.D.

Innovating drug discovery for respiratory diseases using
iPS-cell technology

I have been working as a researcher of iPS-cell technology for respiratory diseases. I am preparing for a start-up based on our
technologies. I have seen many patients with respiratory diseases as a respiratory physician. Now I will give our technologies back topatients as novel drugs.
9

The Elegant Monkeys Ltd.

Idan Lahav

Kenko Technology - Digitizing Human Emotions.

Idan is the VP R&D of The Elegant Monkeys, leading the research and development of Kenko Technology, overcoming challenges andadvancing the technology to where it needs to be. Idan holds a Master of Business Administration in Management of Technology,
Innovation & Entrepreneurship from Tel Aviv University and a Bachelor in Computer Science. Before joining the Elegant Monkeys, Idan
served for 6 years as an officer in an elite intelligence unit for the Israeli Defence Forces and later led development teams for 3 years in
the Israeli start-up ecosystem.